COVID - 19, Statins and other probable treatments

Therapeutics

Use of statins is associated with a reduced risk of mortality among individuals with COVID-19 (Cell metabolism, 24 June)

https://www.cell.com/COVID-19

https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30316-8

Statins are lipid-lowering therapeutics

Anti-inflammatory effects

Proposed as an adjunct therapy for COVID-19

Retrospective study

N = 13,981 patients with COVID-19

1,219 received statins

28-day all-cause mortality

Statins group = 5.2%

Non-statin group = 9.4%

Hazard ratio 0.58

Imply potential benefits of statin therapy in hospitalized subjects with COVID-19

No indications of increased risk using statins

Many potential confounding factors

Need prospective studies

Need randomized controlled trials

Dexamethasone
https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf
Reduced deaths by one third in ventilated patients

Rate ratio 0.65 (p=0.0003)

Reduced deaths by one fifth in patients receiving oxygen only

Rate ratio 0.80 (p=0.0021)

No benefit in patients who did not require respiratory support

Remdesivir

Reduces symptomatic phase from 15 down to 11 days

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

RECOVERY trial

https://www.recoverytrial.net

Large, randomised controlled trial of possible treatments for patients admitted to hospital with COVID-19

11,500 patients have been randomised, 175 NHS hospitals

Lopinavir-Ritonavir
(commonly used to treat HIV)

Low dose Dexamethasone
(a type of steroid, which is typically used to reduce inflammation)

Hydroxychloroquine
(which has now been stopped due to lack of efficacy)

Azithromycin
(a commonly used antibiotic)

Tocilizumab
(an anti-inflammatory treatment given by injection)

Convalescent plasma
(collected from donors who have recovered from COVID-19 and contains
antibodies against the SARS-CoV-2 virus)

India drug

Favipiravir (oral)
https://www.news18.com/news/india/favipiravir-all-you-need-to-know-about-the-new-covid-19-medicine-and-its-effects-on-patients-2679929.html

Inhibits RNA synthesis

Mumbai, Glenmark Pharmaceuticals

Approvals from Drug Controller General of India

What is Favipiravir?

Approved in Japan for treating influenza

Being tested in 18 clinical trials for Covid-19

Based on Phase-3 data, 2 positive outcomes

For emergency restricted use only for treatment of mild to moderate Covid-19

Every patient must have signed informed consent before treatment initiation

Effects

Clinical improvements of up to 88 % in Covid-19

Rapid reduction in viral load by four days

15 days BD

Видео COVID - 19, Statins and other probable treatments канала Dr. John Campbell